ClinicalTrials.gg
CompletedNCT01990534Updated Apr 9, 2021Results posted

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

A Phase 4 interventional study of Brentuximab Vedotin in Hodgkin Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 18 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-09.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
34th of 80
60 · median 52
Started
2014
with 6 others
Phase 4
2 of 80
1 open now
Registered
27th of 80
by date
Lead sponsor
3 of 80
Millennium Pharmaceuticals, Inc.

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 34th largest by enrollment, is one of 7 that started in 2014, is one of 2 in phase 4, and was the 27th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

This phase 4, single-arm, open-label, multicenter study is designed to evaluate the efficacy and safety of brentuximab vedotin as a single agent in adult participants with histologically confirmed CD30+ relapsed or refractory classical Hodgkin Lymphoma who have not received a prior stem cell transplantation (SCT) and are considered to be not suitable for SCT or multiagent chemotherapy at the time of study entry.

Read the detailed description

The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat people who have relapsed or refractory Hodgkin Lymphoma. This study will look at the overall response of people who took brentuximab vedotin.

The study will enroll 60 patients. Participants received:

  • Brentuximab vedotin 1.8 mg/kg

This multicenter trial is being conducted worldwide. The overall time to participate in this study is approximately 6 to 7 years. Participants will make multiple visits to the clinic, and will be contacted by telephone every 3 months for 18 months after the end of treatment (EOT) for follow-up assessment of overall survival and then every 6 months until death, study closure, or 5 years after enrollment of the last participant.

03

Conditions studied

  • Hodgkin Lymphoma

Keywords

  • Lymphoma
  • Hodgkin
  • Relapsed
  • Refractory
  • Antigens, CD30
  • Antibody-Drug Conjugate
  • Antibodies, Monoclonal
  • Monomethyl auristatin E
  • Drug Therapy
  • Immunotherapy
  • Hematologic Diseases
  • Additional Relevant MeSH terms:
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Hodgkin
  • Neoplasms by Histologic Type
  • Neoplasms
  • Lymphoproliferative Disorders
  • Lymphatic Diseases
  • Immunoproliferative Disorders
  • Immune System Diseases
  • Lymphoma, B-Cell
  • Lymphoma, T-Cell
  • Immunologic Factors
  • Physiological Effects of Drugs
  • Pharmacologic Actions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant must meet all of the following inclusion criteria to be enrolled in the study:

  1. Male or female participants 18 years or older, with classical Hodgkin lymphoma (HL), who have previously received at least 1 prior systemic chemotherapeutic regimen
  2. Not suitable for stem cell transplantation (SCT) or multiagent chemotherapy, according to 1 of the following criteria:

    • Disease progression within 90 days of the earliest date of complete remission (CR) or complete remission unconfirmed (CRu) after the end of treatment with multiagent chemotherapeutic regimens and/or radiotherapy
    • Progressive disease during frontline multiagent chemotherapy
    • Disease relapse after treatment with at least 2 chemotherapeutic regimens, including any salvage treatments
  3. Bidimensional
  4. An (ECOG) performance status score of 0 or 1
  5. Female participants who are for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of at the same time, or agree to practice true abstinence.
  6. Male participants who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence.
  7. Clinical laboratory values as specified in the study protocol.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following exclusion criteria are not to be enrolled in the study:

  1. Previous treatment with brentuximab vedotin
  2. Previously received an stem cell transplantation (ASCT) or alloSCT
  3. Known cerebral/meningeal disease, including signs or symptoms suggestive of progressive multifocal leukoencephalopathy (PML), or any history of PML.
  4. Female participants who are lactating and breastfeeding or pregnant.
  5. Known (HIV).
  6. Known surface antigen positive, or known or suspected active infection.
  7. Grade 2 or higher peripheral neuropathy.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Brentuximab Vedotin 1.8 mg/kg

    Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose could be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.

    Drug: Brentuximab Vedotin

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective response rate is defined as the percentage of participants with complete remission (CR) or partial remission (PR) as assessed by an independent review facility (IRF) using International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.

    Time frame: Baseline until disease progression, death or end of study (EOS) (Up to 24 months)

Secondary outcomes

  1. Duration of Response (DOR)

    DOR is defined as the time in months from the date of first documentation of a CR or PR response to the date of first documentation of tumor progression or progressive disease (PD) per IRF assessment according to IWG criteria. CR is defined as the disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites. PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.

    Time frame: From first documented complete or partial remission until disease progression (Up to 24 months)

  2. Progression Free Survival (PFS)

    PFS is defined as time in months from start of study treatment to first documentation of objective tumor progression per IRF assessment or up to death due to any cause, whichever occurs first.

    Time frame: Baseline until disease progression, death or end of treatment (EOT), and then every 3 months up to approximately 6 years

  3. Complete Remission Rate

    Complete remission rate is defined as percentage of participants with CR per IRF response assessment based on IWG criteria are reported. CR is defined as the disappearance of all evidence of disease.

    Time frame: Baseline until disease progression, death or EOS (Up to approximately 6 years)

  4. Duration of Complete Remission

    Duration of CR is defined as the time from the date of first documentation of a CR or to the date of first documentation of tumor progression or progressive disease (PD) per IRF assessment according to IWG criteria. CR is defined as the disappearance of all evidence of disease and PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.

    Time frame: From first documented complete remission until disease progression (up to approximately 6 years)

  5. Overall Survival (OS)

    OS is the time in months from start of study treatment to date of death due to any cause.

    Time frame: Every 3 months for 18 months after EOT, thereafter, every 6 months until the sooner of death, study closure, or 5 years after enrollment of the last participant (up to approximately 6 years)

  6. Percentage of Participants Who Received Hematopoietic SCT

    Time frame: Baseline up to EOS (up to approximately 6 years)

  7. Number of Participants With Adverse Events (AEs), Drug-Related AEs, Grade 3 or Higher AEs, Serious Adverse Events (SAEs), Drug-Related SAEs and Grade 3 or Higher SAEs

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE a serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. AE severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. AEs Grade 3 and higher are severe.

    Time frame: From first dose through 30 days after the last dose of study medication (Up to 24 months)

  8. Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs

    Abnormal clinical laboratory values (serum chemistry and hematology) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.

    Time frame: From the first dose through 30 days after the last dose of study medication (Up to 24 months)

  9. Antibody-drug Conjugate (ADC) Serum Concentrations

    Blood samples were collected and tested for serum concentrations of brentuximab vedotin antibody-drug conjugate.

    Time frame: Cycle 1 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 2 pre-dose and 10 minutes post-dose; Cycle 3 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 4 to 16 pre-dose and 10 minutes post-dose; EOT (Up to 24 months)

  10. Serum Concentration of Total Antibodies (Conjugated and Unconjugated)

    Blood samples were collected and tested for conjugated and unconjugated antibodies.

    Time frame: Cycle 1 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 2 pre-dose and 10 minutes post-dose; Cycle 3 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 4 to 16 pre-dose and 10 minutes post-dose; EOT (Up to 24 months)

  11. Monomethyl Auristatin E (MMAE) Serum Concentrations

    Blood samples were collected and tested for MMAE serum concentrations.

    Time frame: Cycle 1 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 2 pre-dose and 10 minutes post-dose; Cycle 3 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 4 to 16 pre-dose and 10 minutes post-dose; EOT (Up to 24 months)

  12. Number of Participants With Antitherapeutic Antibodies (ATA)

    Blood samples were collected to assess the immunogenicity of brentuximab vedotin (ATA development) using a laboratory test. Confirmed ATA-positive response was categorized as transient (defined as 1 or 2 post-Baseline confirmed ATA-positive responses) and persistent (defined as more than 2 post-Baseline confirmed ATA positive responses) and neutralizing ATA (nATA) status. The confirmed ATA-positive samples were assessed for ATA titer and delineated into having high or low titers.

    Time frame: Day 1 of every 3-week cycle up to 16 cycles and EOT (Up to 24 months)

07

Results

Posted May 5, 2017

Participant flow

Participants took part in the study at 18 investigative sites in Czech Republic, Germany, Malaysia, Poland, Spain, Thailand and Turkey, from 14 March 2014 to 12 March 2020.

Participant flow — Overall Study
MilestoneBrentuximab Vedotin 1.8 mg/kg
Started60
Completed25
Not completed35
Withdrew: Death22
Withdrew: Progressive disease3
Withdrew: Protocol violation1
Withdrew: Withdrawal of informed consent2
Withdrew: Symptomatic deterioration1
Withdrew: Withdrawal by subject3
Withdrew: Reason not specified2
Withdrew: Lost to follow-up1

Outcome measures

PrimaryObjective Response Rate (ORR)

Objective response rate is defined as the percentage of participants with complete remission (CR) or partial remission (PR) as assessed by an independent review facility (IRF) using International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.

Time frame:
Baseline until disease progression, death or end of study (EOS) (Up to 24 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsBrentuximab Vedotin 1.8 mg/kg
Objective Response Rate (ORR)50 (37 to 63)
SecondaryDuration of Response (DOR)

DOR is defined as the time in months from the date of first documentation of a CR or PR response to the date of first documentation of tumor progression or progressive disease (PD) per IRF assessment according to IWG criteria. CR is defined as the disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites. PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.

Time frame:
From first documented complete or partial remission until disease progression (Up to 24 months)
Reported as:
Median · months
Duration of Response (DOR)
monthsBrentuximab Vedotin 1.8 mg/kg
Duration of Response (DOR)4.6 (3.42 to 7.85)
SecondaryProgression Free Survival (PFS)

PFS is defined as time in months from start of study treatment to first documentation of objective tumor progression per IRF assessment or up to death due to any cause, whichever occurs first.

Time frame:
Baseline until disease progression, death or end of treatment (EOT), and then every 3 months up to approximately 6 years
Reported as:
Median · months
Progression Free Survival (PFS)
monthsBrentuximab Vedotin 1.8 mg/kg
Progression Free Survival (PFS)4.8 (2.96 to 5.32)
SecondaryComplete Remission Rate

Complete remission rate is defined as percentage of participants with CR per IRF response assessment based on IWG criteria are reported. CR is defined as the disappearance of all evidence of disease.

Time frame:
Baseline until disease progression, death or EOS (Up to approximately 6 years)
Reported as:
Number · percentage of participants
Complete Remission Rate
percentage of participantsBrentuximab Vedotin 1.8 mg/kg
Complete Remission Rate13 (6 to 25)
SecondaryDuration of Complete Remission

Duration of CR is defined as the time from the date of first documentation of a CR or to the date of first documentation of tumor progression or progressive disease (PD) per IRF assessment according to IWG criteria. CR is defined as the disappearance of all evidence of disease and PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.

Time frame:
From first documented complete remission until disease progression (up to approximately 6 years)
Reported as:
Median · months
Duration of Complete Remission
monthsBrentuximab Vedotin 1.8 mg/kg
Duration of Complete Remission6.1 (2.10 to NA)
SecondaryOverall Survival (OS)

OS is the time in months from start of study treatment to date of death due to any cause.

Time frame:
Every 3 months for 18 months after EOT, thereafter, every 6 months until the sooner of death, study closure, or 5 years after enrollment of the last participant (up to approximately 6 years)
Reported as:
Median · months
Overall Survival (OS)
monthsBrentuximab Vedotin 1.8 mg/kg
Overall Survival (OS)NA (NA to NA)
SecondaryPercentage of Participants Who Received Hematopoietic SCT
Time frame:
Baseline up to EOS (up to approximately 6 years)
Reported as:
Number · percentage of participants
Percentage of Participants Who Received Hematopoietic SCT
percentage of participantsBrentuximab Vedotin 1.8 mg/kg
Percentage of Participants Who Received Hematopoietic SCT53
SecondaryNumber of Participants With Adverse Events (AEs), Drug-Related AEs, Grade 3 or Higher AEs, Serious Adverse Events (SAEs), Drug-Related SAEs and Grade 3 or Higher SAEs

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE a serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. AE severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. AEs Grade 3 and higher are severe.

Time frame:
From first dose through 30 days after the last dose of study medication (Up to 24 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Drug-Related AEs, Grade 3 or Higher AEs, Serious Adverse Events (SAEs), Drug-Related SAEs and Grade 3 or Higher SAEs
ParticipantsBrentuximab Vedotin 1.8 mg/kg
Any AEs52
Grade 3 or higher AEs21
Drug-related AEs41
Drug-related Grade 3 or higher AEs11
SAEs11
Drug-related SAEs3
SecondaryNumber of Participants With Abnormal Clinical Laboratory Values Reported as AEs

Abnormal clinical laboratory values (serum chemistry and hematology) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.

Time frame:
From the first dose through 30 days after the last dose of study medication (Up to 24 months)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs
ParticipantsBrentuximab Vedotin 1.8 mg/kg
Neutrophil count decreased2
Lymphocyte count decreased1
Alanine aminotransferase increased2
Aspartate aminotransferase increased2
Gamma-glutamyltransferase increased1
Blood thyroid stimulating hormone increased1
Platelet count decreased1
Haemoglobin decreased1
Blood alkaline phosphatase increased1
Blood lactate dehydrogenase increased1
SecondaryAntibody-drug Conjugate (ADC) Serum Concentrations

Blood samples were collected and tested for serum concentrations of brentuximab vedotin antibody-drug conjugate.

Time frame:
Cycle 1 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 2 pre-dose and 10 minutes post-dose; Cycle 3 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 4 to 16 pre-dose and 10 minutes post-dose; EOT (Up to 24 months)
Reported as:
Mean · ng/mL
Antibody-drug Conjugate (ADC) Serum Concentrations
ng/mLBrentuximab Vedotin 1.8 mg/kg
Cycle 1 Day 1, Pre-Dose0.00 ± 0.000
Cycle 1 Day 1, 10 minutes Post-Dose35504.65 ± 10226.104
Cycle 1 Day 2, 24 hours Post-Dose14517.67 ± 4481.312
Cycle 1 Day 15, 336 hours Post-Dose1410.43 ± 1946.525
Cycle 2 Day 1, Pre-Dose526.42 ± 350.467
Cycle 2 Day 1, 10 minutes Post-Dose37118.32 ± 11678.088
Cycle 3 Day 1, Pre-Dose2283.30 ± 7552.322
Cycle 3 Day 1, 10 minutes Post-Dose35878.77 ± 12724.898
Cycle 3 Day 2, 24 hours Post-Dose14737.82 ± 4512.358
Cycle 3 Day 15, 336 hours Post-Dose1586.45 ± 680.955
Cycle 4 Day 1, Pre-Dose1313.56 ± 2566.360
Cycle 4 Day 1, 10 minutes Post-Dose42915.34 ± 28221.764
Cycle 5 Day 1, Pre-Dose1117.01 ± 637.637
Cycle 5 Day 1, 10 minutes Post-Dose36418.77 ± 10041.935
Cycle 6 Day 1, Pre-Dose1231.45 ± 714.383
Cycle 6 Day 1, 10 minutes Post-Dose39000.95 ± 12484.458
Cycle 7 Day 1, Pre-Dose1285.91 ± 712.625
Cycle 7 Day 1, 10 minutes Post-Dose38814.82 ± 12471.299
Cycle 8 Day 1, Pre-Dose1413.98 ± 782.391
Cycle 8 Day 1, 10 minutes Post-Dose39027.22 ± 9919.251
Cycle 9 Day 1, Pre-Dose1277.18 ± 594.603
Cycle 9 Day 1, 10 minutes Post-Dose38359.15 ± 13421.064
Cycle 10 Day 1, Pre-Dose1498.44 ± 754.721
Cycle 10 Day 1, 10 minutes Post-Dose39890.12 ± 5376.038
Cycle 11 Day 1, Pre-Dose1511.35 ± 461.907
Cycle 11 Day 1, 10 minutes Post-Dose39132.17 ± 6316.541
Cycle 12 Day 1, Pre-Dose1479.38 ± 397.816
Cycle 12 Day 1, 10 minutes Post-Dose39955.13 ± 7821.656
Cycle 13 Day 1, Pre-Dose1423.56 ± 415.744
Cycle 13 Day 1, 10 minutes Post-Dose37609.69 ± 4563.601
Cycle 14 Day 1, Pre-Dose1185.62 ± 422.664
Cycle 14 Day 1, 10 minutes Post-Dose38282.29 ± 10324.023
Cycle 15 Day 1, Pre-Dose2279.42 ± 2919.545
Cycle 15 Day 1, 10 minutes Post-Dose39068.14 ± 7981.110
Cycle 16 Day 1, Pre-Dose1452.23 ± 429.731
Cycle 16 Day 1, 10 minutes Post-Dose38414.73 ± 9427.315
End of Treatment1515.30 ± 6413.367
SecondarySerum Concentration of Total Antibodies (Conjugated and Unconjugated)

Blood samples were collected and tested for conjugated and unconjugated antibodies.

Time frame:
Cycle 1 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 2 pre-dose and 10 minutes post-dose; Cycle 3 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 4 to 16 pre-dose and 10 minutes post-dose; EOT (Up to 24 months)
Reported as:
Mean · ng/mL
Serum Concentration of Total Antibodies (Conjugated and Unconjugated)
ng/mLBrentuximab Vedotin 1.8 mg/kg
Cycle 1 Day 1, Pre-Dose0.00 ± 0.000
Cycle 1 Day 1, 10 minutes Post-Dose37329.59 ± 17724.247
Cycle 1 Day 2, 24 hours Post-Dose23248.90 ± 8228.938
Cycle 1 Day 15, 336 hours Post-Dose2791.49 ± 1413.452
Cycle 2 Day 1, Pre-Dose1254.86 ± 774.586
Cycle 2 Day 1, 10 minutes Post-Dose39801.87 ± 12914.837
Cycle 3 Day 1, Pre-Dose2645.22 ± 5685.914
Cycle 3 Day 1, 10 minutes Post-Dose36461.28 ± 11144.634
Cycle 3 Day 2, 24 hours Post-Dose27071.46 ± 8069.489
Cycle 3 Day 15, 336 hours Post-Dose4033.28 ± 1760.094
Cycle 4 Day 1, Pre-Dose\2600.73 ± 2275.881
Cycle 4 Day 1, 10 minutes Post-Dose41823.31 ± 11761.223
Cycle 5 Day 1, Pre-Dose2690.61 ± 1254.886
Cycle 5 Day 1, 10 minutes Post-Dose43786.57 ± 15470.979
Cycle 6 Day 1, Pre-Dose2806.17 ± 1021.877
Cycle 6 Day 1, 10 minutes Post-Dose44936.89 ± 13827.929
Cycle 7 Day 1, Pre-Dose3889.94 ± 6201.351
Cycle 7 Day 1, 10 minutes Post-Dose41840.20 ± 12552.597
Cycle 8 Day 1, Pre-Dose2932.19 ± 1089.138
Cycle 8 Day 1, 10 minutes Post-Dose42013.77 ± 12754.334
Cycle 9 Day 1, Pre-Dose2959.26 ± 970.811
Cycle 9 Day 1, 10 minutes Post-Dose37300.95 ± 13442.910
Cycle 10 Day 1, Pre-Dose3189.16 ± 1484.258
Cycle 10 Day 1, 10 minutes Post-Dose38910.05 ± 6169.552
Cycle 11 Day 1, Pre-Dose3393.07 ± 1160.604
Cycle 11 Day 1, 10 minutes Post-Dose41238.25 ± 8081.750
Cycle 12 Day 1, Pre-Dose3270.44 ± 965.895
Cycle 12 Day 1, 10 minutes Post-Dose37550.64 ± 12459.906
Cycle 13 Day 1, Pre-Dose3406.00 ± 1067.414
Cycle 13 Day 1, 10 minutes Post-Dose35694.80 ± 3720.378
Cycle 14 Day 1, Pre-Dose2723.01 ± 1286.457
Cycle 14 Day 1, 10 minutes Post-Dose40848.64 ± 8704.538
Cycle 15 Day 1, Pre-Dose3111.63 ± 941.200
Cycle 15 Day 1, 10 minutes Post-Dose37091.56 ± 6644.258
Cycle 16 Day 1, Pre-Dose3159.38 ± 1017.679
Cycle 16 Day 1, 10 minutes Post-Dose39266.07 ± 9358.163
End of Treatment2340.49 ± 6715.837
SecondaryMonomethyl Auristatin E (MMAE) Serum Concentrations

Blood samples were collected and tested for MMAE serum concentrations.

Time frame:
Cycle 1 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 2 pre-dose and 10 minutes post-dose; Cycle 3 pre-dose and 10 minutes, 24 hours and 336 hours post-dose; Cycle 4 to 16 pre-dose and 10 minutes post-dose; EOT (Up to 24 months)
Reported as:
Mean · pg/mL
Monomethyl Auristatin E (MMAE) Serum Concentrations
pg/mLBrentuximab Vedotin 1.8 mg/kg
Cycle 1 Day 1, Pre-Dose0.78 ± 5.976
Cycle 1 Day 1, 10 minutes Post-Dose591.09 ± 662.608
Cycle 1 Day 2, 24 hours Post-Dose6056.44 ± 3850.457
Cycle 1 Day 15, 336 hours Post-Dose746.12 ± 1123.502
Cycle 2 Day 1, Pre-Dose140.11 ± 111.036
Cycle 2 Day 1, 10 minutes Post-Dose539.38 ± 593.150
Cycle 3 Day 1, Pre-Dose130.62 ± 84.152
Cycle 3 Day 1, 10 minutes Post-Dose484.88 ± 701.402
Cycle 3 Day 2, 24 hours Post-Dose3076.75 ± 2330.510
Cycle 3 Day 15, 336 hours Post-Dose442.63 ± 259.360
Cycle 4 Day 1, Pre-Dose150.95 ± 123.841
Cycle 4 Day 1, 10 minutes Post-Dose497.20 ± 520.110
Cycle 5 Day 1, Pre-Dose153.95 ± 123.337
Cycle 5 Day 1, 10 minutes Post-Dose392.50 ± 320.346
Cycle 6 Day 1, Pre-Dose158.89 ± 109.024
Cycle 6 Day 1, 10 minutes Post-Dose369.53 ± 260.871
Cycle 7 Day 1, Pre-Dose185.91 ± 147.311
Cycle 7 Day 1, 10 minutes Post-Dose363.83 ± 237.883
Cycle 8 Day 1, Pre-Dose136.37 ± 86.947
Cycle 8 Day 1, 10 minutes Post-Dose303.43 ± 202.351
Cycle 9 Day 1, Pre-Dose142.30 ± 114.794
Cycle 9 Day 1, 10 minutes Post-Dose224.52 ± 159.833
Cycle 10 Day 1, Pre-Dose100.78 ± 57.270
Cycle 10 Day 1, 10 minutes Post-Dose253.73 ± 113.311
Cycle 11 Day 1, Pre-Dose158.09 ± 169.963
Cycle 11 Day 1, 10 minutes Post-Dose302.60 ± 175.869
Cycle 12 Day 1, Pre-Dose175.02 ± 141.192
Cycle 12 Day 1, 10 minutes Post-Dose382.52 ± 428.255
Cycle 13 Day 1, Pre-Dose146.76 ± 61.758
Cycle 13 Day 1, 10 minutes Post-Dose258.78 ± 108.871
Cycle 14 Day 1, Pre-Dose82.13 ± 22.661
Cycle 14 Day 1, 10 minutes Post-Dose204.29 ± 121.162
Cycle 15 Day 1, Pre-Dose133.78 ± 59.213
Cycle 15 Day 1, 10 minutes Post-Dose246.63 ± 98.399
Cycle 16 Day 1, Pre-Dose163.39 ± 114.821
Cycle 16 Day 1, 10 minutes Post-Dose264.63 ± 103.269
End of Treatment139.72 ± 220.211
SecondaryNumber of Participants With Antitherapeutic Antibodies (ATA)

Blood samples were collected to assess the immunogenicity of brentuximab vedotin (ATA development) using a laboratory test. Confirmed ATA-positive response was categorized as transient (defined as 1 or 2 post-Baseline confirmed ATA-positive responses) and persistent (defined as more than 2 post-Baseline confirmed ATA positive responses) and neutralizing ATA (nATA) status. The confirmed ATA-positive samples were assessed for ATA titer and delineated into having high or low titers.

Time frame:
Day 1 of every 3-week cycle up to 16 cycles and EOT (Up to 24 months)
Reported as:
Count of participants · Participants
Number of Participants With Antitherapeutic Antibodies (ATA)
ParticipantsBrentuximab Vedotin 1.8 mg/kg
ATA Positive21
Transient Positive17
Persistently Positive4
ATA Titer Low (≤25)21
ATA Titer High (>25)0

Adverse events

Collected over First dose of study drug up to 30 days post last dose of study drug (Up to 24 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brentuximab Vedotin 1.8 mg/kg22/60 (36.7%)11/60 (18.3%)51/60 (85%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventBrentuximab Vedotin 1.8 mg/kg
BronchitisInfections and infestations1/60
PneumoniaInfections and infestations1/60
Device related sepsisInfections and infestations1/60
Septic shockInfections and infestations1/60
Dengue feverInfections and infestations1/60
Urinary tract infectionInfections and infestations1/60
Viral infectionInfections and infestations1/60
Serum sickness-like reactionImmune system disorders1/60
Anaphylactic reactionImmune system disorders1/60
TachycardiaCardiac disorders1/60
Most frequent other events
Showing 10 of 103
Most frequent other events
EventBrentuximab Vedotin 1.8 mg/kg
PyrexiaGeneral disorders11/60
Peripheral sensory neuropathyNervous system disorders7/60
NeutropeniaBlood and lymphatic system disorders6/60
DiarrhoeaGastrointestinal disorders6/60
Neuropathy peripheralNervous system disorders6/60
AnaemiaBlood and lymphatic system disorders5/60
NauseaGastrointestinal disorders5/60
Upper respiratory tract infectionInfections and infestations5/60
PolyneuropathyNervous system disorders5/60
VomitingGastrointestinal disorders4/60

Baseline characteristics

Safety Population included all enrolled participants who received at least 1 dose of brentuximab vedotin.

Age, Continuous
Age, Continuous(years)Brentuximab Vedotin 1.8 mg/kg
Mean35.4 ± 13.83
Sex: Female, Male
Sex: Female, Male(Participants)Brentuximab Vedotin 1.8 mg/kg
Female24
Male36
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brentuximab Vedotin 1.8 mg/kg
Hispanic or Latino2
Not Hispanic or Latino58
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brentuximab Vedotin 1.8 mg/kg
American Indian or Alaska Native0
Asian18
Native Hawaiian or Other Pacific Islander0
Black or African American0
White42
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Brentuximab Vedotin 1.8 mg/kg
Czech Republic3
Germany2
Malaysia8
Poland26
Spain2
Thailand10
Turkey9
Baseline Height
Baseline Height(cm)Brentuximab Vedotin 1.8 mg/kg
Mean171.0 ± 9.66
Baseline Weight
Baseline Weight(kg)Brentuximab Vedotin 1.8 mg/kg
Mean70.3 ± 19.41
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Brentuximab Vedotin 1.8 mg/kg
Mean23.864 ± 5.4085
08

Study locations

18 sites
  • Praha, Prague, Czechia
  • Brno, Czechia
  • Heidelberg, Baden Wuerttemberg, Germany
  • Koeln, Germany
  • Georgetown, Penang, Malaysia
  • Ampang, Selangor, Malaysia
  • Kuala Lumpur, Malaysia
  • Gdansk, Poland
  • Krakow, Poland
  • Warszawa, Poland
  • Pamplona, Navarra, Spain
  • Madrid, Spain
  • Bangkoknoi, Bangkok, Thailand
  • Patumwan, Bangkok, Thailand
  • Ratchathewi, Bangkok, Thailand
  • Izmir, Bornova, Turkey
  • Ankara, Turkey
  • Izmir, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Mar 2016, 24 months.

Results were first posted in May 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2013
First posted
Nov 21, 2013
StartActual
Mar 14, 2014
Primary completionActual
Mar 24, 2016
CompletionActual
Mar 12, 2020
Results first posted
May 5, 2017
Last update
Apr 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01990534
Responsible party
Sponsor
First posted
Nov 21, 2013
Start date
Mar 14, 2014
Primary completion
Mar 24, 2016
Completion
Mar 12, 2020
Results posted
May 5, 2017
Last update
Apr 9, 2021

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion